A feature of most cancers is heterogeneity with regard to treatment response, recurrence and propensity for metastasis. Biomarkers that decipher this heterogeneity, either independently or in addition to current staging systems can help to guide the suitability of radical surgery and chemoradiotherapy, as well as a tailored approach to follow-up. Despite the promise that prognostic biomarkers hold, relatively few have reached clinical practice. This is because of a failure to translate findings from preclinical models to the clinic, a lack of rigorous prospective biomarker validation studies and poor reproducibility between such studies.

In the past two decades, much scientific endeavour has focused on the role that the immune system has in cancer development ([@bib54]; [@bib12]). Immune cells contribute to cancer progression, preparation of the premetastatic niche ([@bib37]) and outgrowth of cancer cells at distant sites. Cytokines are the master regulators of protumourigenic immune cells, orchestrating their recruitment from the bone marrow and blood to the tumour and polarising their phenotype once within the tumour microenvironment. These soluble mediators can also promote intravasation of tumour cells or their migration to metastatic sites, drive angiogenesis and inhibit cytotoxic T-cell activity ([@bib3]; [@bib29]; [@bib5]). Certain cytokines may therefore be able to provide prognostic information by identifying tumours that are likely to metastasise or display therapeutic resistance ([@bib26]).

The chemokine CXCL12 (SDF1) binds to the chemokine receptor CXCR4 and is constitutively expressed in tissues that serve as sites for metastasis including the lung, bone marrow and liver. Cancer cells migrate to these organs in a CXCL12-dependent manner ([@bib49]; [@bib39]). Preclinical evidence suggests that migration of cancer cells towards CXCL12 in metastatic sites is dependent on simultaneous gain of CXCR4 expression and loss of CXCL12 in the tumour cell, enabling movement away from the primary tumour and towards the metastatic niche ([@bib61], [@bib60]; [@bib33]). However, this experimentally validated hypothesis is at odds with findings demonstrating that CXCL12 is upregulated in cancer tissues relative to their normal counterparts and that high CXCL12 expression in some human tumours correlates with cancer dedifferentiation and increased tumour grade and stage ([@bib52]; [@bib21]; [@bib28]; [@bib63]).

Given the complex and multifaceted role that CXCL12 has in the progression of primary cancer to metastasis, the prognostic benefit of determining CXCL12 expression in cancer patients is unclear. In an attempt to address this issue, we have performed a meta-analysis of CXCL12 protein expression in the tumour or plasma of cancer patients with the primary independent variable being high *vs* low CXCL12 level. Our primary aims were to determine firstly whether CXCL12 expression predicts survival in cancer patients, and secondly, whether CXCL12 measurement can be considered a valid prognostic biomarker in cancer.

Materials and Methods
=====================

This meta-analysis was performed in accordance with the Meta-analysis of Observational studies in Epidemiology (MOOSE) group ([@bib47]) and Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidance ([@bib32]).

Identification of relevant literature
-------------------------------------

MEDLINE (PubMed) and EMBASE (Ovid) were search on 10 November 2016 by a health-care librarian (TP) using the strategy shown in [Supplementary Figures 1 and 2](#sup1){ref-type="supplementary-material"}. All abstracts generated from the search strategy were read and the full text of selected publications was viewed to determine whether the inclusion criteria were met. References from included studies were also hand searched to identify further studies for inclusion.

Inclusion/exclusion criteria
----------------------------

Studies in humans with any solid cancer reporting the effect of CXCL12 expression on absolute, cancer-specific and/or recurrence-free survival were included. We accepted publications reporting any means of CXCL12 protein quantification including ELISA of serum or tumour lysates, or histological analysis of tumour samples. Included studies must have analysed surgical resection histology rather than tumour biopsy. Studies were excluded if they analysed RNA only, or performed a synthesis of publicly available proteomics or RNA data, as were studies of \<20 patients. Studies were also excluded if they were not published in English and duplicated data sets from the same institution were also excluded.

Authors were contacted via email if their publication met the inclusion/exclusion criteria, but reported insufficient information for inclusion in the analysis. If no response was obtained they were contacted a second time within 4 weeks.

Assessment of publication quality and risk of bias
--------------------------------------------------

The Quality in Prognostic Studies (QUIPS) tool was used to determine risk of bias ([@bib15]). Two authors (HS and AGW) independently assessed each publication meeting the inclusion criteria for the quality domains set out in the QUIPS tool and any discrepancies in their assessment were resolved by joint analysis of the quality domain in question. Risk of bias for each domain was reported using a traffic light system, with red, orange or green indicating a high, moderate or low risk of bias, respectively.

Data extraction and statistical analysis
----------------------------------------

Data was extracted by one author (AGW) into a spreadsheet and cross-checked by a second author (HS). In all included studies, the independent variable under observation was the level of CXCL12 expression classified as high *vs* low, as defined by each study. The natural logarithm and standard error of the hazard ratio were calculated for outcome measures in each study. Pooled estimates were presented as forest plots and analysed using the random-effects model (DerSimonian and Laird), performed using Review Manager Version 5.3 (Cochrane Collaboration, Oxford, UK). Heterogeneity between studies was assessed using the Cochran Q statistic (*χ*^2^ test) and *I*^2^. Heterogeneity was considered high, medium or low if ≥75%, 50--75% or \<50%, respectively ([@bib17]). Funnel plots were constructed for overall, disease-specific and recurrence-free survival analyses and assessed by visual inspection. Subgroup analysis was performed to determine the relationship between CXCL12 expression and outcome in specific cancer types for overall survival. A *P*-value\<0.05 throughout was considered statistically significant. We did not correct the *P*-value for multiple comparisons within our subgroup analysis as the Cochrane Handbook (V.5.1.0) ([@bib16]) currently recommends against this.

Results
=======

Search results
--------------

The study flow is shown in [Figure 1](#fig1){ref-type="fig"}. A total of 38 studies were included in the meta-analysis of one or more outcome measures totalling 5807 patients ([Table 1](#tbl1){ref-type="table"}). Twenty-eight studies reported absolute survival, 16 recurrence-free survival and 4 reported cancer-specific survival. A further 18 studies met the inclusion criteria, but failed to report sufficient data to be included. Of these studies, five authors responded to requests for further data. Of the 11 who failed to respond, 5 reported no association between CXCL12 expression and outcome in the original manuscript.

Study demographics
------------------

The demographics of included studies can be seen in [Table 1](#tbl1){ref-type="table"}. The total study period ranged from 1982 to 2014, although in 27% of publications, the study period was not identifiable. Forty-seven per cent of studies analysed patients from Australasia, 39% from Europe, 11% from North America and 3% from Africa and 30% of studies analysed data from more than 200 patients. Eighteen studies analysed patients with gastrointestinal cancer (49%), 7 with gynaecological cancer (19%), 4 with breast cancer (11%), 3 with urological cancer (8%) and 2 with lung cancer (5%). The proportion of patients considered to express high levels of CXCL12 varied widely from 18.9% ([@bib57]) to 89.5% ([@bib45]). The median follow-up period ranged from 4.9 months in a study of metastatic colorectal cancer ([@bib48]) to 167 months in a study of ovarian cancer ([@bib36]) and 13 studies (35%) did not provide the median follow-up period.

Study methodology and assessment of study quality
-------------------------------------------------

The technical detail for included studies, study methodology and technique for CXCL12 protein quantification is shown in [Table 2](#tbl2){ref-type="table"}, while an analysis of risk of bias as determined using the QUIPS tool is shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. There were 3 studies that analysed serum CXCL12 concentration and 34 studies that quantified tumour protein expression using IHC. We did not identify any study that quantified CXCL12 expression in protein from tumour lysate. Most studies simultaneously analysed the expression of other factors with CXCR4 analysed by 23 studies. The antigen retrieval technique and details of the antibody used, sufficient that the methodology could be repeated by readers, were documented by 16 studies (43%). Interestingly, one study reported the use of an antibody with specificity for CXCR4 for the analysis of CXCL12 ([@bib19]).

The method for defining low and high CXCL12 expression level was reported in 89% of studies, with 65% using an arbitrary method not related to data distribution and only 22% of studies determining CXCL12 value cutoffs based on ROC curve analysis. In 10 studies (26%), the CXCL12 expression data was linked to follow-up data collected in a prospective manner.

Survival analysis
-----------------

The pooled HR for overall survival in patients with high CXCL12 expression compared with low expression was 1.39 (95% CI: 1.17--1.65, *P*=0.0002), but with a significant degree of heterogeneity (*I*^2^=86%) ([Figure 2](#fig2){ref-type="fig"}), while the pooled HR for recurrence-free survival was 1.12 (95% CI: 0.82--1.53, *P*=0.48), again with a high degree of study heterogeneity (*I*^2^=85%) ([Figure 3](#fig3){ref-type="fig"}). The pool HR for cancer-specific survival, which was only analysed in four studies, was 1.67 (95% CI: 0.43--6.50, *P*=0.46) again with high study heterogeneity (*I*^2^=87%) (results not shown). Funnel plots for overall, recurrence-free and cancer-specific survival demonstrated no evidence of publication bias or small study effects ([Figure 4](#fig4){ref-type="fig"}).

Subgroup analysis
-----------------

Following subgroup analysis, high CXCL12 expression served as a marker of reduced overall survival in oesophagogastric (HR 2.08; 95% CI: 1.31--3.33, *P*=0.002), pancreatic (HR 1.54; 95% CI: 1.21--1.97, *P*=0.0005) and lung (HR 1.37; 95% CI: 1.08--1.75, *P*=0.01) cancers ([Figure 5](#fig5){ref-type="fig"}). For colorectal and ovarian cancer, however, there was no relationship between CXCL12 expression and overall survival (HR 1.21; 95% CI: 0.64--2.51, *P*=0.49) and (HR 1.23; 95% CI: 0.75--2.03, *P*=0.42), respectively. For breast cancer patients, high CXCL12 predicted better overall survival (HR 0.5; 95% CI: 0.38--0.66, *P*\<0.00001). Of note, aside from colorectal cancer, statistical heterogeneity across studies was significantly lower in subgroup analyses compared with the analysis of all studies combined.

Relatively fewer studies published data for recurrence-free survival, but where sufficient data was available, it broadly supported the findings for absolute survival. We were able to identify at least two studies reporting recurrence-free survival for pancreatic, breast or colon cancer ([Figure 6](#fig6){ref-type="fig"}).

We also performed further subgroup analyses based on the nature of follow-up data collection (prospective *vs* retrospective), study size (\>200 patients *vs* \<200 patients) or method for defining CXCL12 expression cutoff, reasoning that such analysis might help differentiate studies with a higher level of bias. However, this approach failed to eliminate statistical heterogeneity, which was shared between study types evenly (data not shown).

Discussion
==========

The primary objective of this meta-analysis was to determine whether CXCL12 expression was associated with survival in cancer patients. We found that high CXCL12 expression was associated with reduced absolute survival in patients with oesophagogastric, pancreatic or lung cancer, while the converse was the case for breast cancer patients. Indeed, the major cause of heterogeneity in our meta-analysis resulted from heterogeneity in the relationship between CXCL12 expression and outcome between breast and other cancer types. Our data indicate that determination of CXCL12 expression could be useful for predicting outcome in these cancer types. Although studies of RNA expression were excluded from this meta-analysis, published studies that have assessed CXCL12 mRNA expression in oesophageal ([@bib11]) or breast cancer ([@bib40]) support our findings, with an association between increased CXCL12 expression and adverse outcome in oesophageal cancer, but the converse in breast cancer.

The cause of the different effect of high CXCL12 expression and outcome in breast compared with other cancers is unclear. The publications of breast, pancreatic, lung and oesophagogastric cancer included in our study all analysed primary rather than metastatic tumours; thus, differences are unlikely to result from sampling differences between cancer types. However, they may result from clinicobiological differences between these cancers.

Thus, breast cancer is rarely fatal unless metastatic, whereas oesophagogastric, lung and pancreatic cancers often cause mortality through local invasion. CXCL12 is able to promote local invasion of cancer cells, while loss of CXCL12 promotes tumour cell migration to organs expressing high levels of CXCL12 such as the liver, bone marrow and lung. Breast cancers may therefore rely on downregulation of CXCL12 to metastasise, whereas in pancreatic, oesophagogastric and lung tumours, high CXCL12 expression may be associated with poor outcome because it promotes local invasion, in turn contributing to mortality.

Alternatively, differences between breast and other cancer types may reflect systemic differences between the demographics of the studies, or the methodologies used. It should also be considered that the source of CXCL12 within the tumour may be important. The majority of included studies did not investigate the cellular source of CXCL12, and while the immunohistochemical images presented in most publications indicate the primary source of CXCL12 is the tumour cell, it is possible that stromal and tumour cell CXCL12 production have different roles in cancer progression. Finally, there is significant redundancy in the chemokine network such that analysis of a single chemokine alone may be insufficient. Thus, the relative ratio of CXCL12 to its receptors CXCR4 and/or CXCR7 may be a better indicator of CXCL12 activity ([@bib27]; [@bib59]) and there may be differences in these ratios between cancer types.

Our second objective was to determine whether CXCL12 measurement can be used as a prognostic biomarker in cancer patients. The gold standard evidence level for a prognostic biomarker study is a randomised controlled trial (RCT) designed in such a way that participants are randomised to the prognostic test or a standard prognostic factor and the treatment received dependent on the results of the prognostic test. This type of trial is difficult to perform, requires a very large sample size to be adequately powered and is at significant risk of confounding ([@bib44]).

The retrospective analysis of archived tissue specimens collected as part of an RCT may provide as good an indication of the value of a prognostic marker as an RCT of the marker itself, as can the retrospective analysis of tissues linked to prospectively collected follow-up data (a prospective--retrospective design) ([@bib44]). In contrast, truly retrospective biomarker studies, where follow-up data is generated retrospectively, are at high risk of bias. We were only able to identify one study that used RCT-generated follow-up data ([@bib48]) and while a number of other studies were of a prospective--retrospective nature, a significant number were purely retrospective and therefore at risk of bias. This is supported by our analysis of bias using the QUIPS tool, which demonstrated that the majority of studies suffered from at least a moderate risk of bias.

It is however reassuring that the funnel plots generated from studies reporting absolute and recurrence-free survival demonstrate no evidence of publication bias. This is supported by the fact that of the 18 studies that met the inclusion criteria, but reported inadequate outcome data to be included in the meta-analysis, fewer than 50% found that CXCL12 was not associated with outcome; a figure lower than the percentage in the included literature. This suggests that nonsignificant findings with respect to association between CXCL12 expression and outcome are frequently published and were well represented in our analysis.

For a prognostic biomarker to be useful, it must display analytic and clinical validity, as well as clinical utility. Of the studies meeting the inclusion criteria, none robustly determined the validity of the quantification method used and several provided insufficient information such that the method could not be replicated. As a result, the proportion of patients in each study defined as displaying high CXCL12 expression varied considerably. Although such variation may represent true biological differences between tumour types or the patient populations being studied, these factors are unlikely to be the only explanation, as there were significant differences in the proportion of patients with high CXCL12 expression in studies of the same cancer types.

Furthermore, a range of antibodies were used with a sensitivity or specificity for CXCL12 that was not thoroughly determined by the research group, while only two studies repeated their analysis in an independent validation cohort. Based on these findings, although we have identified an association between CXCL12 expression and cancer survival, a standardised, agreed method for CXCL12 quantification has not been reached, and, therefore, CXCL12 can at best be considered an exploratory biomarker at the present time ([@bib10]; [@bib4]). Studies are now needed that accurately report the comparison of several methods for CXCL12 measurement in a prospective--retrospective manner in order that a consensus is reached as to the most appropriate test methodology to take forward for further investigation.

The potential clinical validity of CXCL12 is tested in the subgroup analysis presented here. These data indicate that CXCL12 has clinical validity as a biomarker for breast, pancreatic, lung and oesophagogastric cancer. Studies of colon cancer, whether primary or metastatic, demonstrated heterogenous results over a large number of patients, indicating that measuring CXCL12 alone in colon cancer patients is less likely to be useful for prognostication. Despite this, two colorectal cancer studies assessed the effect of the CXCL12:CXCR4 ratio on survival, with both finding that this approach provided prognostic information. Indeed, the publications by [@bib45] and [@bib7] found that patients with a combination of low CXCL12 and high CXCR4 expression in the primary tumour experienced reduced recurrence-free or overall survival, respectively. Unfortunately, we were unable to identify other studies that combined the measure of CXCL12 and CXCR4 expression in this way, but the data from these studies indicate that this approach may provide more useful information than measuring either factor alone.

The data identified in our meta-analysis provide only limited information about the precise clinical utility of CXCL12 in specific groups of cancer patients. This is in part because of our broad inclusion criteria that identified a heterogeneous set of studies, and also because of a failure of many included studies to define adequately their cancer population. We found that even simple demographic data such as age, sex and tumour stage was not always reported. Future studies in this area should therefore clearly report the analysis of CXCL12 expression in a subset of cancer patients that are defined on the basis of clinical, histopathological and preferably genomic data such that the clinical utility of CXCL12 in clearly defined cancer patients can be better determined.

In summary, the strengths of this meta-analysis are a wide search strategy identifying multiple studies from differing populations and a pragmatic subgroup analysis highlighting potential differences in the relationship between CXCL12 expression and prognosis between cancer types. Through critical and systematic appraisal, this review has led to guidance points that, if followed, will ensure the generation of higher quality data in the investigation of CXCL12 as a prognostic biomarker. These strengths need to be balanced against the fact that our conclusions are drawn from predominantly retrospectively analyses of survival data, which are by definition prone to bias. The majority of included studies also failed to blind the outcome assessor to participants CXCL12 status, leading to a risk of reporter bias in such studies. Overall, the quality of research in this field needs to improve if progress is to be made in better defining the role of CXCL12 as a prognostic biomarker.
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![**Forrest plot of overall survival for all studies meeting the inclusion criteria listed in order of effect size.**](bjc2017134f2){#fig2}

![**Forrest plot of recurrence-free survival for all studies meeting the inclusion criteria in order of effect size.**](bjc2017134f3){#fig3}

![**Funnel plots for included studies reporting overall (left) and recurrence-free survival (right).**](bjc2017134f4){#fig4}

![**Subgroup analysis by cancer type demonstrating meta-analysis of high *vs* low CXCL12 expression for overall survival.**](bjc2017134f5){#fig5}

![**Subgroup analysis by cancer type demonstrating meta-analysis of high *vs* low CXCL12 expression for recurrence-free survival.**](bjc2017134f6){#fig6}

###### Demographics of included studies

  **First author**                       **Year of publication**  **Study period**   **Country**                **Cancer type**           **No. of patients**   **Age \*mean (s.d**.) ^**\$**^**median (range)**    **% female**  **% high CXCL12 expression**    **Median follow-up**
  ------------------------------------- ------------------------- ------------------ -------------------------- ------------------------- --------------------- -------------------------------------------------- -------------- ------------------------------ ----------------------
  [@bib13]                                        2016            ?                  China                      Pancreatic                182                   ^\$^63 (34--85)                                         34.7      34.6                                    12.6
  Guo cohort 2 ([@bib13])                         2016            ?                  China                      Pancreatic                153                   ^\$^65 (38--90)                                         45.1      77.1                                    10.9
  [@bib53]                                        2016            1997--2007         Japan                      Oesophageal               79                    ^\$^59 (44--79)                                         89.9      78.45                                    68
  [@bib45]                                        2016            1993--1996         Norway                     Colonic                   263                   \*61.9 (9.3)                                             52       73.0                                     ?
  Stanisavljević cohort 2) ([@bib45])             2016            2007--2011         Norway                     Colonic                   239                   \*73.5 (11.9)                                            51       89.5                                     ?
  [@bib34]                                        2016            2004--2014         Japan                      Gastric                   70                    ?                                                        ?        48.6                                    37.8
  [@bib6]                                         2016            2007--2011         Holland                    Colonic (metastatic)      52                    \*58 (12)                                               56.6      53.9                                    22.5
  [@bib46]                                        2016            1992--2004         Germany                    Lung (NSCLC)              295                   ?                                                       6.9       53.2                                     ?
  [@bib20]                                        2016            2005--2009         Japan                      Gastric                   110                   ?                                                       28.2      58.2                                     ?
  [@bib51]                                        2016            2000--2012         China                      Endometrial               202                   ?                                                       100       52.0                                     ?
  [@bib38]                                        2016            ?                  Germany                    Head and neck             229                   ?                                                       15.3      42.4                                     83
  [@bib22]                                        2016            1999--2009         United States of America   Lung adeno.               303                   ^\$^72 (39--88)                                         35.0      40.6                                     49
  [@bib50]                                        2015            2009--2014         China                      Glioma                    42                    \*44.9 (13)                                             31.0      21.4                                     ?
  [@bib48]                                        2015            ?                  Worldwide                  Metastatic colorectal     611                   ?                                                       37.0      72.2                                    4.9
  [@bib8]                                         2015            2005--2007         China                      Cervical                  130                   ?                                                        ?        60.8                                     68
  [@bib2]                                         2015            1995--2011         Tunisia                    Colorectal                124                   ?                                                       43.5      71.8                                     ?
  [@bib18]                                        2014            ?                  United States of America   Pancreatic                32                    ?                                                       15.6      ?                                        38
  [@bib58]                                        2014            2002--2006         China                      Gastric                   84                    ?                                                       31.3      50.0                                     59
  [@bib30]                                        2014            ?                  Italy                      Colonic                   50                    ^\$^60 (51--58)                                          42       50.0                                     ?
  [@bib7]                                         2014            ?                  Italy                      Rectal                    68                    ?                                                       42.6      77.9                                     64
  [@bib55]                                        2013            2000--2007         Poland                     Endometrial               92                    \*65.1 (9.5)                                            100       34.8                                     ?
  [@bib57]                                        2013            1982--2007         China                      Prostatic                 148                   ^\$^65.8 (34--85)                                        ?        18.9                                     95
  [@bib56]                                        2012            2002--2003         China                      Renal                     97                    ^\$^55.4 (21--81)                                       38.1      48.9                                     ?
  [@bib24]                                        2012            1998--2009         Korea                      Gallbladder carcinoma     72                    ?                                                       54.2      80.6                                     ?
  [@bib43]                                        2012            1985--1999         Holland                    Cervical                  103                   ^\$^48 (24--87)                                         100       76.7                                    137
  [@bib36]                                        2012            1984--1997         United Kingdom             Ovarian                   172                   ^\$^61 (24--90)                                         100       34.3                                    167
  [@bib41]                                        2012            1999--2007         Japan                      Colorectal (metastatic)   92                    ?                                                       37.0      55.4                                     38
  [@bib28]                                        2011            2002--2004         France                     Ovarian                   183                   ^\$^59 (25--77)                                         100       47.0                                     69
  [@bib62]                                        2011            ?                  Australia                  Breast                    236                   ^\$^55 (24--87)                                         100       66.5                                    131
  [@bib23]                                        2010            1995--1999         Japan                      Breast                    223                   ^\$^52 (30--82)                                         100       70.9                                     74
  [@bib25]                                        2010            1990--2005         United States of America   Pancreatic                72                    ^\$^63 (40--80)                                         33.3      34.7                                     ?
  [@bib31]                                        2009            2000--2002         Germany                    Breast                    100                   ?                                                       100       50.0                                     ?
  [@bib1]                                         2009            1996--1997         Japan                      Colorectal                165                   ?                                                       38.8      72.1                                     61
  [@bib14]                                        2009            2000--2003         United States of America   Breast                    237                   ?                                                       100       55.3                                     40
  [@bib9]                                         2008            ?                  United Kingdom             Germ cell                 80                    ^\$^28 (16--65)                                          0        58.8                                    75.6
  [@bib42]                                        2008            1987--1998         Japan                      Oesophageal               214                   ^\$^64 (36--92)                                         8.4       53.7                                     42
  [@bib19]                                        2007            1996--2001         Japan                      Gastric                   185                   ^\$^61 (31--82)                                          29       40.0                                     ?
  [@bib35]                                        2007            ?                  Austria                    Ovarian                   128                   ^\$^59 (28--87)                                         100       68.0                                    43.7

Abbreviation: NSCLC=non-small-cell lung cancer.

Median follow-up is shown in months.

\*(mean), \$(median).

###### Technical details of method for CXCL12 quantification

  **First author**                     **Sample**      **Quantification method**   **Other factors analysed**     **Antigen retrieval method**                             **Sample storage**   **Antibody/ELISA source (CAT number)**                          **Definition of expression level cutoffs**   **Follow-up collection**   **Outcome measures**
  ------------------------------------ --------------- --------------------------- ------------------------------ -------------------------------------------------------- -------------------- --------------------------------------------------------------- -------------------------------------------- -------------------------- ----------------------
  [@bib13]                             Tumour tissue   IHC                         CXCR7                          Autoclave+citrate                                        FFPE                 R&D Systems, Minneapolis, MN, USA                               Arbitrary                                    Retrospective              OS
  Guo cohort 26) ([@bib13])            Tumour tissue   IHC                         CXCR7                          Autoclave+citrate                                        FFPE                 R&D Systems                                                     Arbitrary                                    Retrospective              OS
  [@bib53]                             Tumour tissue   IHC                         CXCR4                          Target retrieval solution (Dako, Santa Clara, CA, USA)   FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Retrospective              RFS
  [@bib45]                             Tumour tissue   IHC                         CXCR4                          Target retrieval solution (Dako)                         FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Prospective                RFS
  Stanisavljević cohort 2 ([@bib45])   Tumour tissue   IHC                         CXCR4                          Target retrieval solution (Dako)                         FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Prospective                RFS
  [@bib34]                             Serum           Protein array               Multiple (\>10)                N/A                                                      Frozen               Bio-Rad Laboratories (Hercules, CA, USA) (Bio-Plex 220 assay)   Data distribution                            Retrospective              OS
  [@bib6]                              Tumour tissue   IHC                         HIF1a, CXCR4, VEGF             ?                                                        FFPE                 R&D Systems                                                     Arbitrary                                    Prospective                OS
  [@bib46]                             Tumour tissue   IHC                         CXCR4, pCXCR4                  ?                                                        FFPE                 Abcam (Cambridge, UK)                                           ROC curve analysis                           Retrospective              OS
  [@bib20]                             Tumour tissue   IHC                         CXCR4                          ?                                                        FFPE                 R&D SystemsAF-310-NA                                            Arbitrary                                    Retrospective              OS
  [@bib51]                             Tumour tissue   IHC                         CXCR4                          ?                                                        FFPE                 Abcam                                                           Arbitrary                                    Retrospective              CSS
  [@bib38]                             Tumour tissue   IHC                         CXCR4                          Heat (100 °C, 60 min)                                    FFPE                 R&D Systems                                                     Arbitrary                                    Retrospective              OS
  [@bib22]                             Tumour tissue   IHC                         Multiple (\>10)                ?                                                        FFPE                 ?                                                               Arbitrary                                    Prospective                OS
  [@bib50]                             Tumour tissue   IHC                         CXCR4                          Citrate (pH 6.0, 100 °C, 15 min)                         FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    ?                          OS
  [@bib48]                             Serum           ELISA                       Multiple (\>10)                n/a                                                      Frozen               Assay Gate (Ijamsville, MD, USA)                                ROC curve analysis                           Prospective                OS, RFS
  [@bib8]                              Tumour tissue   IHC                         N/A                            ?                                                        FFPE                 ?                                                               Arbitrary                                    Retrospective              OS
  [@bib2]                              Tumour tissue   IHC                         CXCR4                          Citrate (pH 9.0, microwave 2--5 min)                     FFPE                 R&D Systems (?)                                                 Arbitrary                                    Retrospective              OS
  [@bib18]                             Tumour tissue   IHC                         CEA, CA19-9, HGF               ?                                                        FFPE                 Biovision (Milpitas, CA, USA) (?)                               ?                                            Prospective                OS, RFS
  [@bib58]                             Tumour tissue   IHC                         N/A                            ?                                                        FFPE                 R&D Systems (MAB350)                                            ROC curve analysis                           Retrospective              OS
  [@bib30]                             Serum           ELISA                       VEGF, PDGF, osteopontin, CEA   N/A                                                      Frozen               Bio-Rad Laboratories (Bio-Plex 220 assay)                       ROC curve analysis                           Prospective                OS, RFS
  [@bib7]                              Tumour tissue   IHC                         CXCR4, CXCR7                   ?                                                        FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Retrospective              OS
  [@bib55]                             Tumour tissue   IHC                         CXCR4, CXCR7                   Epitope Retrieval Solution (Dako)                        FFPE                 Abcam (AB9797)                                                  Arbitrary                                    Retrospective              OS
  [@bib57]                             Tumour tissue   IHC                         VEGF, MMP9                     0.1% zymine (37 °C, 30 min)                              FFPE                 R&D Systems (?)                                                 Arbitrary                                    ?                          RFS
  [@bib56]                             Tumour tissue   IHC                         CXCR4, CXCR7                   Citrate (pH 6.0, 100 °C, 10 min)                         FFPE                 R&D Systems (MAB350)                                            ROC curve analysis                           Retrospective              OS, RFS
  [@bib24]                             Tumour tissue   IHC                         N/A                            Target Retrieval Solution (DAKO)                         FFPE                 R&D Systems (MAB350)                                            ROC curve analysis                           Retrospective              CSS
  [@bib43]                             Tumour tissue   IHC                         N/A                            Citrate (pH 6.0, microwave, 12 min)                      FFPE                 R&D Systems (MAB350)                                            ?                                            Retrospective              RFS
  [@bib36]                             Tumour tissue   IHC                         CXCR4                          EDTA (pH 9.0, microwave, 10 min)                         FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Retrospective              OS
  [@bib41]                             Tumour tissue   IHC                         CXCR4, CD133                   ?                                                        FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Retrospective              OS, RFS
  [@bib28]                             Tumour tissue   IHC                         N/A                            Citrate (pH 6.0, microwave)                              FFPE                 Abcam (AB10395)                                                 Arbitrary                                    Prospective                OS, RFS
  [@bib62]                             Tumour tissue   IHC                         FoxP3                          Tris/EDTA (pH 9.0, microwave)                            FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    retrospective              CSS
  [@bib23]                             Tumour tissue   IHC                         CXCR4                          0.5% Tween-20 in PBS                                     FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    ?                          OS, RFS
  [@bib25]                             Tumour tissue   IHC                         N/A                            EDTA (pH 9.0, 100 °C, 20 min)                            FFPE                 R&D Systems (?)                                                 ROC curve analysis                           prospective                OS, RFS
  [@bib31]                             Tumour tissue   IHC                         CXCR4                          ?                                                        FFPE                 Dianova (Hamburg, Germany) (?)                                  ROC curve analysis                           ?                          OS, RFS
  [@bib1]                              Tumour tissue   IHC                         N/A                            Citrate (pH 6.0, 121 °C, 10 min)                         FFPE                 R&D Systems (?)                                                 Arbitrary                                    Prospective                OS, RFS
  [@bib14]                             Tumour tissue   IHC                         CXCR4                          ?                                                        FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    ?                          OS
  [@bib9]                              Tumour tissue   IHC                         CXCR4                          ?                                                        FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Retrospective              RFS
  [@bib42]                             Tumour tissue   IHC                         CXCR4                          Citrate buffer (120 °C, 10 min)                          FFPE                 R&D Systems (MAB350)                                            Arbitrary                                    Retrospective              OS
  [@bib19]                             Tumour tissue   IHC                         N/A                            ?                                                        FFPE                 R&D Systems (MAB172)                                            ?                                            ?                          OS
  [@bib35]                             Tumour tissue   IHC                         CXCR4                          ?                                                        FFPE                 R&D Systems (MAB350)                                            ?                                            ?                          OS

Abbreviations: CSS=cancer specific survival; ELISA=enzyme-linked immunosorbent assay; FFPE=formalin-fixed paraffin-embedded; IHC=immunohistochemistry; N/A=not applicable; OS=overall survival; RFS=recurrence-free survival.
